Beijing Jiasitang Biopharmaceutical

Beijing Jiasitang Biopharmaceutical is a clinical-stage biotechnology company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology. The company's research focuses on critical signaling pathways in cancer, particularly the RAS/MAPK pathway, to address unmet medical needs in solid tumors. Its lead candidate, JST-001, is a potent and selective inhibitor of SHP2 (Src homology 2 domain-containing protein tyrosine phosphatase 2), which is currently undergoing Phase 1 clinical evaluation. Jiasitang aims to develop precision medicines that can be used as monotherapies or in combination with other targeted therapies to overcome drug resistance. The company has successfully advanced its lead program into clinical trials in both China and the United States, demonstrating its global development capabilities. Supported by prominent venture capital firms, Jiasitang continues to expand its pipeline of targeted therapies for various cancer indications.